Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Amgen

Pharmaceutical intelligence for Amgen with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 4
Assets: 5

Recent signals(3)

ClinicalJune 19, 2026

Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer

Amgen is conducting a trial to compare overall survival in patients with metastatic castration-resistant prostate cancer receiving xaluritamig plus abiraterone versus standard treatments.

ClinicalJune 17, 2026

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.

RegulatoryJune 16, 2026

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

The FDA has approved Bizengri (zenocutuzumab-zbco) for the treatment of NRG1 fusion-positive cholangiocarcinoma.

Upcoming catalysts(1)

Phase II Readout

Amgen — MariTide

Monthly dosing profile could differentiate Amgen in GLP-1/GIP competitive race.

June 25, 2026 · Phase II

Regulatory activity(1)

RegulatoryJune 16, 2026

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

The FDA has approved Bizengri (zenocutuzumab-zbco) for the treatment of NRG1 fusion-positive cholangiocarcinoma.

Clinical activity(2)

ClinicalJune 19, 2026

Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer

Amgen is conducting a trial to compare overall survival in patients with metastatic castration-resistant prostate cancer receiving xaluritamig plus abiraterone versus standard treatments.

ClinicalJune 17, 2026

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.

Competitive activity

No signals indexed for this entity yet.

Assets

Xaluritamig →

Therapeutic areas

NRG1 Fusion-Positive Cholangiocarcinoma →

Oncology · Bispecific Antibodies →

Oncology · NRG1 Fusion-Positive Cholangiocarcinoma →

Oncology · Prostate Cancer →

Pancreatic Adenocarcinoma →

Prostate Cancer →

Indications

NRG1 Fusion-Positive Cholangiocarcinoma →

Pancreatic Adenocarcinoma →

Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.